Disease · MONDO_0100338
Comparisons in its trials82
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 82
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Gepotidacin vs Nitrofurantoin: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 285 of 804 | 200 of 798 | 1,602 | NCT04187144 | Trial comparisons |
| Gepotidacin vs Nitrofurantoin: Number of Participants With Serious Adverse Events (SAEs) | 5 of 804 | 5 of 798 | 1,602 | NCT04187144 | Trial comparisons |
| Gepotidacin vs Nitrofurantoin: deaths from any cause | 0 of 804 | 0 of 798 | 1,602 | NCT04187144 | Trial comparisons |
| Gepotidacin vs Nitrofurantoin: serious adverse events | 5 of 804 | 5 of 798 | 1,602 | NCT04187144 | Trial comparisons |
| Gepotidacin vs Nitrofurantoin: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 266 of 766 | 165 of 760 | 1,526 | NCT04020341 | Trial comparisons |
| Gepotidacin vs Nitrofurantoin: Number of Participants With Serious Adverse Events (SAEs) | 2 of 766 | 3 of 760 | 1,526 | NCT04020341 | Trial comparisons |
| Gepotidacin vs Nitrofurantoin: deaths from any cause | 0 of 766 | 0 of 760 | 1,526 | NCT04020341 | Trial comparisons |
| Gepotidacin vs Nitrofurantoin: serious adverse events | 2 of 766 | 3 of 760 | 1,526 | NCT04020341 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in The Safety Population | 176 of 685 | 176 of 687 | 1,372 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: deaths from any cause | 0 of 685 | 0 of 687 | 1,372 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: serious adverse events | 14 of 685 | 12 of 687 | 1,372 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Clinical Cure at EOT Days the Clinically Evaluable (CE-EOT) Populations | 673 of 677 | 665 of 674 | 1,351 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Clinical Cure at TOC in the CE-TOC Populations | 611 of 641 | 617 of 637 | 1,278 | NCT03788967 | Trial comparisons |
| Eravacycline (Intravenous) vs Ertapenem (Intravenous): deaths from any cause | 3 of 601 | 2 of 600 | 1,201 | NCT03032510 | Trial comparisons |
| Eravacycline (Intravenous) vs Ertapenem (Intravenous): serious adverse events | 11 of 601 | 6 of 600 | 1,201 | NCT03032510 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Sustained Clinical Cure at LFU in the CE-LFU Populations | 556 of 596 | 559 of 596 | 1,192 | NCT03788967 | Trial comparisons |
| CXA-201 as Treatment for cUTI vs Levofloxacin as Treatment for cUTI: serious adverse events | 15 of 533 | 18 of 535 | 1,068 | NCT01345929 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Overall Response (Combined Clinical Cure and Microbiological Eradication) at Test-of-Cure (TOC) in Micro Intent-to-Treat Population | 264 of 449 | 258 of 419 | 868 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Clinical Cure at EOT in the ME-EOT Populations | 437 of 439 | 394 of 401 | 840 | NCT03788967 | Trial comparisons |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: By-Patient Microbiological Eradication at EOT in the ME-EOT Populations | 436 of 439 | 399 of 401 | 840 | NCT03788967 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100338/comparisons